’ psychosocial problems may be targets to prevent unplanned acute care utilization (“readmission”). Methods: The study included 933 unique adult patients admitted to four acute care inpatient facilities within a non-profit community based healthcare system in
Search Results
Joyce LaMori, Kai Zu, Kristina L. Greenwood, Besa Smith, Tyler Smith, and Alaina Lee
Janeen Grant-Sittol, Rani Sittol, Latoya Gayle, Sharde Mcleish, Jodi-Ann Smith, Jason Lofters, Zachary Banbury, Natasha Rastogi, and Tanganyika Barnes
USPSTF lung cancer screening guidelines with annual low-dose computed tomography (LDCT) in an at-risk patient population at the North Hudson Community Action Corporation (NHCAC), a federally qualified healthcare center in Englewood, NJ. Method : A single
Adam C. Powell, Christopher T Lugo, Jeremy T Pickerell, James W Long, Amin J Mirhadi, and Bryan A Loy
significantly less likely to deem orders appropriate for older patients (OR: 0.97; CI: 0.96-0.98), urban patients (OR: 0.75; CI: 0.61-0.90), and patients with a history of breast MRI (OR: 0.66; CI: 0.54-0.81). Orders for patients from communities with median
Ricardo A Estupinian, Yolaine Jeune-Smith, Stephanie Fortier, Bruce Feinberg, and Ajeet Gajra
the approval of immune checkpoint inhibitors (ICI) in 2015, and expansion to first-line (1L). We sought to assess the preferences of community hematologists/oncologists (cH/O) in 1L treatment for advanced NSCLC. Methods : Between June and August 2021
Ran Jin, Neil Accortt, Darcie Sandschafer, Tatiana Lawrence, and Reshma Mahtani
geographically diverse, and includes more than 2.2 million US cancer patients (primarily treated in a community setting) from >280 cancer clinics. Results: First use of trastuzumab-anns was in early stage BC (eBC) and occurred 4 days after product launch. 2
Sandhya Mehta, Winghan Kwong, Angelica Falkenstein, Melissa Pavilack, and Jonathan Kish
private community practices) and provided data on 325 HER2-ve mBC patients. Based on the most recent test, 49%(n=160) met HER2 low criteria, 50%(n=161) had IHC0 and 1% had undetermined (n=3) or HER2+ve(n=1) results. Among HER2 low patients [median age=65
Yu-Jing Huang, Paula D. Ryan, Gregory L. Price, Gebra Cuyun Carter, Kristin M. Sheffield, Emily Nash Smyth, Claudia Morato Guimaraes, Sarah Rybowski, Jonathan Rajkumar, and Lavanya Sudharshan
(16.9%), hospitalization (3.5%), and emergency room visit (5.1%). Conclusions: This descriptive analysis provides insights into pt characteristics, real-world AEs, and related outcomes with CDK 4 & 6i within a US community oncology network.
Chunlin Qian, Elizabeth Marrett, Winghan Jacqueline Kwong, and Laura Q.M. Chow
mean (SD) TTT was 85.3 (72.6) days. Patients who were younger, black or from rural communities had significantly longer TTT compared to their counterparts. In addition, patients who did not receive surgery and those with brain metastases had
Petros Grivas, Meaghan Roach, Vivek Pawar, Caroline Huber, Suepattra May-Slatter, Isha Desai, Jane Chang, and Murtuza Bharmal
for 1L regimens is not well defined. Methods: We interviewed US oncologists and oncology nurses in academic and community-based practices. Semi-structured interviews were conducted in August 2020 to explore decision-making processes regarding 1L
Kathy Ruble, Juliana Pare-Blagoev, Lisa Carey, Kimberly Milla, Sydney Henegan, Clifton Thornton, and Lisa Jacobson
their concerns (22%). After physical/health concerns (28%), parents wanted information about resources in the community (21%) and learning difficulties (15%). Post-project parent surveys are planned for January/February 2021. Referrals for NP evaluations
